Back to Results

Semnur Pharmaceuticals Inc (SMNR)

Featured in Today's Top Gainers

Semnur Pharmaceuticals Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing non-opioid treatments for acute and chronic pain. Its lead candidate is SP-102, a viscous gel formulation of a corticosteroid being studied for lumbosacral radicular pain, also known as sciatica, and is currently in a second Phase 3 study. Founded in 2013 and based in Palo Alto, California, the company operates as a subsidiary of Scilex Holding Company. The listed security is common stock on OTC Markets under the symbol SMNR.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
OTC-SMNR
$0.57
-6.2% Downside
Fair
Not available
Not available
Weak
0.0%
November 11, 2026
103.6 M
128.9 M
17.9%
21.1%
-493.6
6.3%
Valuation • Fair Value

Semnur Pharmaceuticals Inc (OTC-SMNR) Fair Value by Valuation Model

Review the available estimates for Semnur Pharmaceuticals Inc (OTC-SMNR), including Comps Fair Value.

Primary Valuation Read

Fair Value

$0.57

Estimated downside of 6.2% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$0.57

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 3 available valuation references for Semnur Pharmaceuticals Inc (OTC-SMNR) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Semnur Pharmaceuticals Inc (OTC-SMNR)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

0 K

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Semnur Pharmaceuticals Inc (OTC-SMNR) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Semnur Pharmaceuticals Inc (OTC-SMNR)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

0

Weak quality score that deserves closer review.

Altman Z-Score

-493.6

Lower score that deserves closer risk review.

FCF / Net Income

6.3%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Semnur Pharmaceuticals Inc (OTC-SMNR). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Semnur Pharmaceuticals Inc (OTC-SMNR)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 11, 2026

Days to Earnings

54

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Semnur Pharmaceuticals Inc (OTC-SMNR), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Semnur Pharmaceuticals Inc (OTC-SMNR) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Semnur Pharmaceuticals Inc (OTC-SMNR) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for Semnur Pharmaceuticals Inc (OTC-SMNR) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Semnur Pharmaceuticals Inc (OTC-SMNR) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Semnur Pharmaceuticals Inc (OTC-SMNR) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

Semnur Pharmaceuticals Inc (OTC-SMNR) Stock FAQ

Data-supported answers about Semnur Pharmaceuticals Inc (OTC-SMNR), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$0.57
Estimated downside 6.2%
Valuation Rating
Overvalued
Estimated downside of 6.2%
Financial Health
Weak
Current financial-health read

The current fair value estimate for Semnur Pharmaceuticals Inc (OTC-SMNR) is $0.57. This implies an estimated downside of 6.2% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 6.2% versus the current market price.

The current financial health read for Semnur Pharmaceuticals Inc (OTC-SMNR) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Semnur Pharmaceuticals Inc (OTC-SMNR) is November 11, 2026.

The latest available data indicates no current dividend yield for Semnur Pharmaceuticals Inc (OTC-SMNR).

The current market capitalization listed for Semnur Pharmaceuticals Inc is 103.6 M.

The current enterprise value listed for Semnur Pharmaceuticals Inc is 128.9 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Semnur Pharmaceuticals Inc is OTC-SMNR, and the stock is listed on OTC Markets.

Semnur Pharmaceuticals Inc (OTC-SMNR) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Semnur Pharmaceuticals Inc is 17.9%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Semnur Pharmaceuticals Inc is 21.1%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,027.7 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 650.6 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 362.4 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 266.2 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 191.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 157.7 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 128.8 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 101.9 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 100.8 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.801 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 45.423 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.198 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.653 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 29.504 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.446 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.628 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Fair Market Cap 11.943 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.202 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.884 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.161 B